Awareness on Hepatitis C
How do we get
Hepatitis C?
Hepatitis C is
a blood-borne illness, meaning it is transmitted via contact with infected
blood. Usually the virus enters the body through a puncture wound on the skin.
Call for abstract : https://hepatitis.euroscicon.com/abstract-submission
Hepatitis C symptoms:
About 70%
to 80% of people with the hepatitis C virus do not have any symptoms,
especially in the early stages. In these people, symptoms may develop years,
even decades later, when liver damage occurs. Others develop symptoms between 2
weeks to 6 months after infection. The average time to develop symptoms is 6 to
7 weeks after acquiring the virus. A person who has hepatitis C infection, but
isn't exhibiting any symptoms can still pass the virus on to others. Hepatitis C
symptoms may include:
- Mild-to-severe fever
- Fatigue
- Abdominal pain
- Loss of appetite
- Nausea
- Vomiting
- Joint pain
- Dark urine
- Clay-colored stool
- Yellowing of the skin (jaundice)
Call for abstract : https://hepatitis.euroscicon.com/abstract-submission
Hepatitis c testing:
If you have any risk
factor for hepatitis C,
Then the next step is to test
for it. Initial testing for hepatitis C has three parts:
The first test:
The HCV antibody test sees if you have been
exposed to the virus.
The second test:
The viral load test and it detects whether you
were merely exposed or if you actually have hep C. If that test is positive,
The third test:
Genotype test is done to find
out what kind of hep C you have.
HCV Antibody Testing: Diagnosing hepatitis C begins with an antibody test. Antibodies to HCV can be detected in the blood, usually within two or three months after the virus enters the body. If a person is positive for HCV antibodies, he or she has been exposed to the virus in the past. About 15 to 25 % of people who are initially infected with HCV are able to clear the virus from their bodies, usually within six months of exposure. The next step is to look for the actual virus in the bloodstream, using a viral load test. If a person has an acute infection, meaning that he or she was recently infected with HCV, antibodies may not have formed yet, so a viral load is necessary to confirm infection.
HCV Viral Load Testing: A health care provider can request a qualitative HCV RNA test to determine if the virus is in a person’s bloodstream. A medical provider can also order a quantitative HCV RNA test to figure out a person’s HCV viral load (the amount of HCV in a measurement of blood). Various methods are used to detect HCV RNA, including TMA (transcription-mediated amplification), PCR (polymerase chain reaction), and bDNA (branched DNA). Qualitative viral load testing tends to be more sensitive than quantitative testing. Viral load testing using PCR or TMA are more sensitive than bDNA testing.
HCV viral load testing is used during treatment to determine how well the medications are working. Increases and decreases in HCV RNA do not correlate to disease progression, so the qualitative viral load test is not very useful outside of treatment. HCV viral load results cannot determine if or when someone with hepatitis C will develop cirrhosis or liver failure.
HCV Genotypic Testing: Genotype refers to the genetic structure or makeup of living organisms. The hepatitis C virus has eight different genotypes, which are numbered in the order of their discovery. (The identification of genotype 8 was announced at the 2017 Liver Meeting.) Each of these genotypes has subtypes, which were lettered in the order that they were discovered. It is important to find out which hepatitis C genotype you have, because it determines the best treatment for you. HCV genotype also helps to predict the likelihood of curing HCV, but improved medications with high cure rates have made this less useful.
Worldwide, HCV genotype 1 is most common, accounting for 46 % of cases. In the United States, 75 % of all HCV infections are genotype 1; genotypes 2, 3 and 4 are less common in the United States, and other genotypes are rare. Genotype 7 was discovered in 2013 and there is only one known case. Two genotype 8 cases were identified in India. It is possible to infected with more than one HCV genotype; this most likely occurs among injection drug users, and people who received contaminated blood products before 1987 (when viral inactivation started), or a blood transfusion before July 1992 (when effective screening procedures were instituted).
HCV Antibody Testing: Diagnosing hepatitis C begins with an antibody test. Antibodies to HCV can be detected in the blood, usually within two or three months after the virus enters the body. If a person is positive for HCV antibodies, he or she has been exposed to the virus in the past. About 15 to 25 % of people who are initially infected with HCV are able to clear the virus from their bodies, usually within six months of exposure. The next step is to look for the actual virus in the bloodstream, using a viral load test. If a person has an acute infection, meaning that he or she was recently infected with HCV, antibodies may not have formed yet, so a viral load is necessary to confirm infection.
HCV Viral Load Testing: A health care provider can request a qualitative HCV RNA test to determine if the virus is in a person’s bloodstream. A medical provider can also order a quantitative HCV RNA test to figure out a person’s HCV viral load (the amount of HCV in a measurement of blood). Various methods are used to detect HCV RNA, including TMA (transcription-mediated amplification), PCR (polymerase chain reaction), and bDNA (branched DNA). Qualitative viral load testing tends to be more sensitive than quantitative testing. Viral load testing using PCR or TMA are more sensitive than bDNA testing.
HCV viral load testing is used during treatment to determine how well the medications are working. Increases and decreases in HCV RNA do not correlate to disease progression, so the qualitative viral load test is not very useful outside of treatment. HCV viral load results cannot determine if or when someone with hepatitis C will develop cirrhosis or liver failure.
HCV Genotypic Testing: Genotype refers to the genetic structure or makeup of living organisms. The hepatitis C virus has eight different genotypes, which are numbered in the order of their discovery. (The identification of genotype 8 was announced at the 2017 Liver Meeting.) Each of these genotypes has subtypes, which were lettered in the order that they were discovered. It is important to find out which hepatitis C genotype you have, because it determines the best treatment for you. HCV genotype also helps to predict the likelihood of curing HCV, but improved medications with high cure rates have made this less useful.
Worldwide, HCV genotype 1 is most common, accounting for 46 % of cases. In the United States, 75 % of all HCV infections are genotype 1; genotypes 2, 3 and 4 are less common in the United States, and other genotypes are rare. Genotype 7 was discovered in 2013 and there is only one known case. Two genotype 8 cases were identified in India. It is possible to infected with more than one HCV genotype; this most likely occurs among injection drug users, and people who received contaminated blood products before 1987 (when viral inactivation started), or a blood transfusion before July 1992 (when effective screening procedures were instituted).
To learn more or globalize
your research in international wide, Join with our international conference.
Call for abstract : https://hepatitis.euroscicon.com/abstract-submission
Hepatitis 2019 Conference
Info:
7th International
Conference on Hepatitis and Liver Diseases (Hepatitis 2019)
to be held in London, UK during May 02-03, 2019.
The conference highlights the theme “Raising awareness and advancement
towards Hepatitis and Liver Diseases”.
The conference
invites Hepatologists, Gastroenterologists, Virologists, Microbiologists,
immunologist, Pathologists, Oncologists, Toxicologists, Researchers, Students,
Young researchers and business delegates across the World.
Hepatitis
2019 Conference is to bring
top experts together and delegates for an in-depth discussion on Hepatitis and Liver diseases. To create awareness for both rural and urban
population about liver disease it should be diagnosed at early stages. The
importance of this conference is to update, clinically relevant audience
regarding the evidence supporting current clinical practices in hepatitis. The
information presented is intended to enhance clinical competence in the diagnosis
and treatment of hepatitis and
liver disease.
Conference Highlights
- Hepatitis B
- Hepatitis C
- Hepatitis A, D & E
- Hepatitis Vaccination
- Hepatitis Clinical Research Trials
- Non-viral Hepatitis
- Epidemiology of Hepatitis
- Hepatocellular Carcinoma
- Liver Diseases
- Metabolic Liver diseases
- Hepato-Biliary Disease
- Liver diseases
- Liver Transplantation and Surgery
- Gastroenterology
- HCV/HIV Coinfection
- Hepatitis Diagnosis and Treatment
- Biliary Astresia
- Hepatotoxicity
- Hepatic Encephalopathy
- Gene expression in Hepatitis
- Clinical Trials
Conference Website: https://hepatitis.euroscicon.com/
#Christmas Offer
20% discount on Registration
Use the discount code : XMAS20
For avail discount visit : https://hepatitis.euroscicon.com/registration/discount
With regards
Joseph Raven
Conference manager | Hepatitis 2019
Email : hepatitisconference@yandex.com
CME Hepatitis conferences 2019 | Hepatitis Conferences 2019 | CME Liver Conferences | Liver Conferences 2019 | CME Hepatitis and Liver Diseases Conferences 2019 | CME Hepatitis and Liver Diseases Meetings | Liver Congress | Liver Conference | Hepatitis 2019 | Gastroenterology conference | Pancreas conference | Liver Cirrhosis Conference | London conference | Hepatitis conference | Healthcare conference | Public awareness conference | Infectious Diseases Conference | International Conference | virology conference | Immunology conference | Gastro conference | Digestive Diseases conference.
#Christmas #HepatitisC #LondonConference #Europe #MedicalConference #Publicawareness #Education #Knowledge
